AHA 2024 - Milton Packer shares the results of the SUMMIT trial, in which the efficacy of the dual GIP/GLP-1RA tirzepatide was examined in patients with HFpEF and obesity. He says: “This is really very exciting news and information. We think it would change the practice of how these patients are treated in the future.”